STAB News and Press, Statera Biopharma Inc. From 03/21/22

FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...

FORT COLLINS, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...

Statera Biopharma (STAB -11.4%) said it advanced research activities that builds upon its STAT-200 platform to improve drug characteristics and clinical benefit beyond opioid receptors. The research is based on the discovery that STAT-200, which was originally designed to antag...

In collaboration with MolSoft, ImQuest, a Statera company, is investigating new, optimized compositions incorporating desirable elements of STAT-200 FORT COLLINS, Colo., March 07, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical comp...

Buying Penny Stocks Today? Here’s What You Need to Know As another interesting day of trading penny stocks gets off, there is a lot for investors to consider. Right now, there are several factors impacting the trajectory of both penny stocks and blue chips . And, because the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re almost done with the week but we still need to go over the biggest pre-market stock movers for Friday! Source: Shutterstock Movings stocks this morning is clinical trial news, ea...

FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Statera Biopharma, Inc. (Nasdaq: STAB), please note an additional sentence has been added to the fifth paragraph. The corrected release follows: Statera Biopharma, Inc....

FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to the U.S. Food and Drug Administra...

—Satish Chandran of Lays Sciences and Physis Pharma, Inc. to join Board of Directors as Steve Barbarick transitions to advisory role— FORT COLLINS, Colo., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or &#x...

Statera Biopharma (NASDAQ:STAB), formerly known as "Cytocom," has reported prelim revenue of $1.49M for 2021. The biopharmaceutical firm reported no revenue in 2020. The growth in revenue was attributed to the acquisition of ImQuest Life Sciences and its subsidiaries by Cytocom in June 2021. ...